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Abstract
Target-specific next-generation sequencing technology was used to analyze 112 genes in adult patients with acute
lymphoblastic leukemia (ALL). This sequencing mainly focused on the specific mutational hotspots. Among the 121
patients, 93 patients were B-ALL (76.9%), and 28 patients (23.1%) were T-ALL. Of the 121 patients, 110 (90.9%) harbored
at least one mutation. The five most frequently mutated genes in T-ALL are NOTCH1, JAK3, FBXW7, FAT1, and NRAS. In
B-ALL, FAT1, SF1, CRLF2, TET2, and PTPN1 have higher incidence of mutations. Gene mutations are different between
Ph+ALL and Ph−ALL patients. B-ALL patients with PTPN11 mutation and T-ALL patients with NOTCH1 and/or FBXW7
mutations showed better survival. But B-ALL with JAK1/JAK2 mutations showed worse survival. The results
suggest that gene mutations exist in adult ALL patients universally, they are related with prognosis.
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To the editor
Acute lymphoblastic leukemia (ALL) represents one of
the most common malignant diseases of childhood,
accounts for about 15 ~ 25% of acute leukemia in adults
[1]. Adult ALL is generally characterized by diverse
biological features, evident clinical heterogeneity, and
worse prognosis than pediatric ALL [2]. With the devel-
opment of genetics in ALL, several new subtypes of ALL
and a series of prognostic-related molecular markers are
put forward [3–5].
In the recent years, with the application of next-
generation sequencing (NGS) technology, genomics has
been extensively developed in both pediatric and adult
ALL patients [6]. Samples and clinical information were
collected from 121 adult ALL patients (Additional file
1:Table S1) with informed consent (ethical approval serial
number is KT2015001-EC-1). These patients were from
the Institute of Hematology and Blood Diseases Hospital,
Chinese Academy of Medical Sciences. Target regions of
112 genes (Additional file 2: Table S2) were selected on
the basis of known or suspected involvement in the patho-
genesis of malignant hematologic disorder and were
enriched and analyzed using a custom targeted NGS gene
panel (Additional file 3). Then, the relationships between
the mutations with higher incidence and the prognosis of
ALL patients were analyzed (Additional file 4).
Of the 121 patients, a total of 110 patients (90.9%)
harbored at least one gene mutation with a median of 2
(0–7) mutations per sample. Thirty-nine patients
(32.2%) had more than 3 gene mutations (Additional file
5: Figure S1). Sixty genes were considered as possible
pathogenic mutations when compared against multiple
databases (Fig. 1a. The top 38 mutated genes were
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listed). The five most frequently mutated genes were
FAT1, NOTCH1, SF1, CRLF2, and NRAS (mutated in
>8% of the cases).
In 28 T-ALL cases, the most common mutated gene
was NOTCH1, with a mutation rate of 39.3% (n = 11),
then JAK3, FBXW7, FAT1, NRAS, CREBBP, DNM2 (mu-
tated in >10% of the cases) (Additional file 6: Figure
S2A). In B-ALL, FAT1 was the most accepted mutated
gene (10.75%), then SF1, CRLF2, TET2, PTPN11, NRAS,
CREBBP, JAK2, DIS3, MPL, and KML2D (mutated in
>5% of the cases) (Additional file 6: Figure S2B). In Ph+
B-ALL, FAT1, CRLF2, SF1, EP300, and CREBBP genes
mutated at higher incidences (Additional file 6: Figure
S2C). However, PTPN11, SF1, TET2, NRAS, JAK2, DIS3,
and FAT1 gene mutations occurred popularly in Ph−B-
ALL (Additional file 6: Figure S2D).
The main signaling pathways involved in this targeted
NGS gene panel were transcription factor/regulator, Ras/
protein phosphatase/MARK signaling pathway, JAK-STAT
pathway, splicing and mRNA processing regulation,
epigenetic modulators, and so on [7–9]. Frequencies of
different signaling pathways involved are listed in Fig. 1b.
Genes involved in these signaling pathways are listed in
Additional file 7:Table S3.
In full cohort, the median overall survival (OS) was
34.88 (1.25–74.55) months, median relapse-free
survival (RFS) was 30.85 (0–73.55) months and 3-year
OS and RFS rates were 49%. In the full cohort,
patients with PTPN11 mutation had a better progno-
sis compared with patients without PTPN11 mutation
(p = 0.040, p = 0.047), and the patients with JAK2mutation
(7/117) had a worse prognosis compared with patients
without JAK2 mutation (p = 0.031, p = 0.018) (Additional
file 8: Figure S3). B-ALL patients with PTPN11 mutation
(7/93) had a better OS and RFS compared with those
without PTPN11mutation (p= 0.041, p = 0.047) (Additional
file 9: Figure S4).
In T-ALL, patients with NOTCH1 and/or FBXW7
mutations had a better OS and RFS than patients without
these mutations (p = 0.035, p = 0.048) (Additional file 10:
Figure S5).
Multivariate analysis of OS and RFS showed that
the prognostic factors included JAK2 mutations (OS;
p= 0.045, RFS; p = 0.021) in the total adult ALL
patients cohort. JAK1 mutations (OS; p = 0.004, RFS;
p = 0.005) and JAK2 mutations (OS; p = 0.049, RFS; p
= 0.044) for Ph−B-ALL. The data was summarized in
Table 1.
Fig. 1 Frequency of gene mutations and related signal pathways in ALL subtypes. a Frequency of the top 38 gene mutations in different ALL
subtypes, which are shown in indicated colors. b Frequency of gene mutations involved in different functional pathways
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In summary, our study suggests that gene mutations
exists in adult ALL patients universally, involving a
variety of signaling pathways. The frequency and species
are varied in different types of ALL. B-ALL patients were
accompanied with PTPN11 mutation for good prognosis,
while abnormal JAK family often indicates poor progno-
sis. In T-ALL, mutation of NOTCH1 and/or FBXW7 in-
dicates good prognosis.
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